Studies muscle health in people with lung cancer during treatment
Checks whether muscle mass and strength relate to treatment tolerance in lung cancer patients.
Plain-language title generated from the registry record
Registry title: Sarcopenia and Cachexia in Patients With Lung Cancer
Key facts
- Where
- Næstved, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with any type or stage of lung cancer who are about to start cancer treatment and are expected to live more than 3 months.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Lung cancer of all types and stages, with cancer treatment planned.
Main reasons for not taking part
- Another competing cancer
- Pregnancy
- Severe physical or cognitive disability that prevents physical testing and informed consent
- Not able to read and understand Danish
Read by machine on 9 November 2026.
Where in Denmark
- Zealand University HospitalNæstved, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zealand University Hospital
- Trial code
- NCT06730685
- Record updated
- 12 February 2026
- Original description
The PHILICA study investigates whether muscle mass, muscle strength, and muscle function are associated with treatment tolerance, quality of life and survival in patients with lung cancer. It also aims to explore why some patients face challenges in completing their treatment. The findings may contribute to improved strategies for supporting patients and developing more precise and individualized treatment plans in the future.Read full original descriptionShow less
PHILUCA: The Development of Muscle Mass, Muscle Strength, and Muscle Function in Patients With Lung Cancer During Cancer Treatment
The PHILICA study investigates whether muscle mass, muscle strength, and muscle function are associated with treatment tolerance, quality of life and survival in patients with lung cancer. It also aims to explore why some patients face challenges in completing their treatment. The findings may contribute to improved strategies for supporting patients and developing more precise and individualized treatment plans in the future.
Inclusion: Age ≥ 18 years of age; Diagnosed with lung cancer (all types and stages) and scheduled for oncological treatment; More than 3 months expected survival.
Exclusion: Competing cancer; Pregnancy; Severe physical or cognitive disabilities preventing physical testing and informend consent; Not able to read and understand Danish.